Preliminary Demonstration of a Radiation-dose Response Via Ultrasound-based Skin Measurements in Breast Cancer Radiotherapy
T. Liu,S. A. Woodhouse,S. F. Shaitelman,J. Zhou,T. J. Wong,E. J. Yoshida,G. J. Kutcher,W. J. Curran
DOI: https://doi.org/10.1016/j.ijrobp.2009.07.445
2009-01-01
Abstract:Purpose/Objective(s)To quantitatively evaluate acute skin toxicity using multiple ultrasound scans throughout radiation treatment and to effectively demonstrate a radiation therapy (RT) dose response in breast cancer radiotherapy.Materials/MethodsWe conducted an ultrasonic imaging study to examine the trajectory of the RT dose response in breast radiotherapy. Skin thickness was measured as a proxy for fibrosis and edema. Six breast cancer patients were enrolled in an IRB-approved study. All patients received a standard course of radiation: 50.4 Gy followed by an electron boost of 10.0 Gy at the lumpectomy site. A baseline ultrasound scan was performed one week prior to radiation therapy, followed by scans at weekly intervals throughout radiation treatment and a scan one month post treatment. Patients were imaged on both breasts with a 14-MHz ultrasound linear probe, in a supine position, at the 12, 3, 6, and 9 o'clock axes as well as at the lumpectomy site. Scans taken on the untreated breast served as a control. Each scan set took approximately five minutes to acquire. Skin thickness was measured from the ultrasound images, beginning at the entry ultrasound echo signal and ending at the border between the dermis and fat. We compared ultrasound findings with weekly clinical assessments based on RTOG acute toxicity and with patient self-assessments at treatment completion.ResultsA total of 423 digital ultrasound images were acquired and examined. For all patients, average skin thickness of the untreated breast was 2.0 mm (range 1.6 to 3.7). Average skin thickness of the treated breast increased with radiation dose received during treatment (p = 0.001) and was 3.2 mm (range 2.0 to 5.5) at treatment completion. Large variations in RT dose response occurred among patients: maximum skin thickness increase ranged from 11% to 62% over the course of treatment. Severe skin thickening (> 50% increase) was observed in 2 out of 6 patients, with initial thickening observed between 3000 cGy and 4000 cGy. Greater skin thickening over time was correlated with severity of pain in patient self-assessments. The ultrasound skin evaluations were consistent with RTOG breast toxicity assessments.ConclusionsWe demonstrated quantitative ultrasound as an objective means of assessing acute RT dose response in breast radiation therapy. This study is the first of its kind to document the trajectory of skin toxicity development. Our next step is to conduct a larger scale clinical study that compares various treatment techniques, such as hypofractionation, partial breast IMRT and MammoSite. We hope that with this non-invasive imaging technique, physicians will gain a better understanding of individual patient's RT dose response and therefore, be able to design personalized treatment regimens. Purpose/Objective(s)To quantitatively evaluate acute skin toxicity using multiple ultrasound scans throughout radiation treatment and to effectively demonstrate a radiation therapy (RT) dose response in breast cancer radiotherapy. To quantitatively evaluate acute skin toxicity using multiple ultrasound scans throughout radiation treatment and to effectively demonstrate a radiation therapy (RT) dose response in breast cancer radiotherapy. Materials/MethodsWe conducted an ultrasonic imaging study to examine the trajectory of the RT dose response in breast radiotherapy. Skin thickness was measured as a proxy for fibrosis and edema. Six breast cancer patients were enrolled in an IRB-approved study. All patients received a standard course of radiation: 50.4 Gy followed by an electron boost of 10.0 Gy at the lumpectomy site. A baseline ultrasound scan was performed one week prior to radiation therapy, followed by scans at weekly intervals throughout radiation treatment and a scan one month post treatment. Patients were imaged on both breasts with a 14-MHz ultrasound linear probe, in a supine position, at the 12, 3, 6, and 9 o'clock axes as well as at the lumpectomy site. Scans taken on the untreated breast served as a control. Each scan set took approximately five minutes to acquire. Skin thickness was measured from the ultrasound images, beginning at the entry ultrasound echo signal and ending at the border between the dermis and fat. We compared ultrasound findings with weekly clinical assessments based on RTOG acute toxicity and with patient self-assessments at treatment completion. We conducted an ultrasonic imaging study to examine the trajectory of the RT dose response in breast radiotherapy. Skin thickness was measured as a proxy for fibrosis and edema. Six breast cancer patients were enrolled in an IRB-approved study. All patients received a standard course of radiation: 50.4 Gy followed by an electron boost of 10.0 Gy at the lumpectomy site. A baseline ultrasound scan was performed one week prior to radiation therapy, followed by scans at weekly intervals throughout radiation treatment and a scan one month post treatment. Patients were imaged on both breasts with a 14-MHz ultrasound linear probe, in a supine position, at the 12, 3, 6, and 9 o'clock axes as well as at the lumpectomy site. Scans taken on the untreated breast served as a control. Each scan set took approximately five minutes to acquire. Skin thickness was measured from the ultrasound images, beginning at the entry ultrasound echo signal and ending at the border between the dermis and fat. We compared ultrasound findings with weekly clinical assessments based on RTOG acute toxicity and with patient self-assessments at treatment completion. ResultsA total of 423 digital ultrasound images were acquired and examined. For all patients, average skin thickness of the untreated breast was 2.0 mm (range 1.6 to 3.7). Average skin thickness of the treated breast increased with radiation dose received during treatment (p = 0.001) and was 3.2 mm (range 2.0 to 5.5) at treatment completion. Large variations in RT dose response occurred among patients: maximum skin thickness increase ranged from 11% to 62% over the course of treatment. Severe skin thickening (> 50% increase) was observed in 2 out of 6 patients, with initial thickening observed between 3000 cGy and 4000 cGy. Greater skin thickening over time was correlated with severity of pain in patient self-assessments. The ultrasound skin evaluations were consistent with RTOG breast toxicity assessments. A total of 423 digital ultrasound images were acquired and examined. For all patients, average skin thickness of the untreated breast was 2.0 mm (range 1.6 to 3.7). Average skin thickness of the treated breast increased with radiation dose received during treatment (p = 0.001) and was 3.2 mm (range 2.0 to 5.5) at treatment completion. Large variations in RT dose response occurred among patients: maximum skin thickness increase ranged from 11% to 62% over the course of treatment. Severe skin thickening (> 50% increase) was observed in 2 out of 6 patients, with initial thickening observed between 3000 cGy and 4000 cGy. Greater skin thickening over time was correlated with severity of pain in patient self-assessments. The ultrasound skin evaluations were consistent with RTOG breast toxicity assessments. ConclusionsWe demonstrated quantitative ultrasound as an objective means of assessing acute RT dose response in breast radiation therapy. This study is the first of its kind to document the trajectory of skin toxicity development. Our next step is to conduct a larger scale clinical study that compares various treatment techniques, such as hypofractionation, partial breast IMRT and MammoSite. We hope that with this non-invasive imaging technique, physicians will gain a better understanding of individual patient's RT dose response and therefore, be able to design personalized treatment regimens. We demonstrated quantitative ultrasound as an objective means of assessing acute RT dose response in breast radiation therapy. This study is the first of its kind to document the trajectory of skin toxicity development. Our next step is to conduct a larger scale clinical study that compares various treatment techniques, such as hypofractionation, partial breast IMRT and MammoSite. We hope that with this non-invasive imaging technique, physicians will gain a better understanding of individual patient's RT dose response and therefore, be able to design personalized treatment regimens.